<p>It&#8217;s always incredible for a company developing a new innovation in an existing field when its tech yields satisfying results. Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition &#8211; from $87.8 in mid-June all [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --></p> . A Global Investing Platform helping investors from India & Middle East invest in US listed
We care about your data, and we'd love to use cookies to make your experience better.